- Home
- SI vs AVIR Comparison
SI vs AVIR Comparison
Compare SI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SI
- AVIR
- Stock Information
- Founded
- SI 2009
- AVIR 2012
- Country
- SI United States
- AVIR United States
- Employees
- SI N/A
- AVIR N/A
- Industry
- SI Medical/Dental Instruments
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- SI Health Care
- AVIR Health Care
- Exchange
- SI Nasdaq
- AVIR Nasdaq
- Market Cap
- SI 248.2M
- AVIR 290.4M
- IPO Year
- SI 2025
- AVIR 2020
- Fundamental
- Price
- SI $13.19
- AVIR $3.12
- Analyst Decision
- SI Strong Buy
- AVIR Hold
- Analyst Count
- SI 5
- AVIR 1
- Target Price
- SI $19.60
- AVIR $6.00
- AVG Volume (30 Days)
- SI 143.6K
- AVIR 389.5K
- Earning Date
- SI 11-10-2025
- AVIR 11-06-2025
- Dividend Yield
- SI N/A
- AVIR N/A
- EPS Growth
- SI N/A
- AVIR N/A
- EPS
- SI N/A
- AVIR N/A
- Revenue
- SI $37,324,000.00
- AVIR N/A
- Revenue This Year
- SI $40.62
- AVIR N/A
- Revenue Next Year
- SI $33.40
- AVIR N/A
- P/E Ratio
- SI N/A
- AVIR N/A
- Revenue Growth
- SI 64.07
- AVIR N/A
- 52 Week Low
- SI $11.51
- AVIR $2.46
- 52 Week High
- SI $17.94
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- SI N/A
- AVIR 53.21
- Support Level
- SI N/A
- AVIR $2.78
- Resistance Level
- SI N/A
- AVIR $2.94
- Average True Range (ATR)
- SI 0.00
- AVIR 0.10
- MACD
- SI 0.00
- AVIR 0.04
- Stochastic Oscillator
- SI 0.00
- AVIR 92.11
About SI Shoulder Innovations Inc. Common Stock
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).